U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C43H65N5O10
Molecular Weight 812.0054
Optical Activity UNSPECIFIED
Defined Stereocenters 13 / 13
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TELITHROMYCIN

SMILES

CC[C@]1([H])[C@]2(C)[C@@]([H])([C@@]([H])(C)C(=O)[C@]([H])(C)C[C@](C)([C@@]([H])([C@@]([H])(C)C(=O)[C@@]([H])(C)C(=O)O1)O[C@@]3([H])[C@@]([H])([C@]([H])(C[C@@]([H])(C)O3)N(C)C)O)OC)N(CCCCn4cc(-c5cccnc5)nc4)C(=O)O2

InChI

InChIKey=LJVAJPDWBABPEJ-PNUFFHFMSA-N
InChI=1S/C43H65N5O10/c1-12-33-43(8)37(48(41(53)58-43)19-14-13-18-47-23-31(45-24-47)30-16-15-17-44-22-30)27(4)34(49)25(2)21-42(7,54-11)38(28(5)35(50)29(6)39(52)56-33)57-40-36(51)32(46(9)10)20-26(3)55-40/h15-17,22-29,32-33,36-38,40,51H,12-14,18-21H2,1-11H3/t25-,26-,27+,28+,29-,32+,33-,36-,37-,38-,40+,42-,43-/m1/s1

HIDE SMILES / InChI

Molecular Formula C43H65N5O10
Molecular Weight 812.0054
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 13 / 13
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00976 https://en.wikipedia.org/wiki/Telithromycin

French pharmaceutical company Hoechst Marion Roussel (later Sanofi-Aventis) began phase II/III clinical trials of telithromycin (HMR-3647) in 1998. Telithromycin was approved by the European Commission in July 2001 and subsequently went on sale in October 2001. In the US, telithromycin received U.S. Food and Drug Administration (FDA) approval on April 1, 2004 Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek. After significant controversy regarding safety and research fraud, the US Food and Drug Administration sharply curtailed the approved uses of the drug in 2007. Telithromycin is a semi-synthetic erythromycin derivative. It is created by substituting a ketogroup for the cladinose sugar and adding a carbamate ring in the lactone ring. An alkyl-aryl moiety is attached to this carbamate ring. Furthermore, the carbon at position 6 has been methylated, as is the case in clarithromycin, to achieve better acid-stability. For the treatment of Pneumococcal infection, acute sinusitis, acute bacterial tonsillitis, acute bronchitis and bronchiolitis, lower respiratory tract infection and lobar (pneumococcal) pneumonia. KETEK tablets contain telithromycin, a semisynthetic antibacterial in the ketolide class for oral administration. Telithromycin blocks protein synthesis by binding to domains II and V of 23S rRNA of the 50S ribosomal subunit. By binding at domain II, telithromycin retains activity against gram-positive cocci (e.g., Streptococcus pneumoniae) in the presence of resistance mediated by methylases (erm genes) that alter the domain V binding site of telithromycin. Telithromycin may also inhibit the assembly of nascent ribosomal units.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
KETEK

Approved Use

KETEK tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years old and above.

Launch Date

1.07317441E12
Curative
KETEK

Approved Use

KETEK tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years old and above.

Launch Date

1.07317441E12
Curative
KETEK

Approved Use

KETEK tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years old and above.

Launch Date

1.07317441E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.27 mg/L
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.8 mg/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.07 mg/L
1600 mg single, oral
dose: 1600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.829 mg/L
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.48 mg/L
1600 mg 1 times / day steady-state, oral
dose: 1600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.9 mg/L
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.27 μg/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.9 μg/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12.5 mg × h/L
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.57 mg × h/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
23.1 mg × h/L
1600 mg single, oral
dose: 1600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.5 mg × h/L
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
30.2 mg × h/L
1600 mg 1 times / day steady-state, oral
dose: 1600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.25 mg × h/L
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12.5 μg × h/mL
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.25 μg × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.81 h
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.68 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.13 h
1600 mg single, oral
dose: 1600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7.7 h
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18.7 h
1600 mg 1 times / day steady-state, oral
dose: 1600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7.16 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9.81 h
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.16 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
35%
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.436
unhealthy, 13-72
n = 232
Health Status: unhealthy
Condition: Group A beta-hemolytic streptococcal tonsillitis/pharyngitis
Age Group: 13-72
Sex: M+F
Population Size: 232
Sources: Page: p.436
Disc. AE: Allergic reaction, Alanine aminotransferase increase...
AEs leading to
discontinuation/dose reduction:
Allergic reaction
Alanine aminotransferase increase
Aspartate aminotransferase increase
Lactate dehydrogenase increased
Sources: Page: p.436
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.1598
unhealthy, 17–64
n = 140
Health Status: unhealthy
Condition: asthma
Age Group: 17–64
Sex: M+F
Population Size: 140
Sources: Page: p.1598
Other AEs: Diarrhea, Nausea...
Other AEs:
Diarrhea (9.8%)
Nausea (5.3%)
Nausea (3.8%)
Sources: Page: p.1598
1600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources: Page: p.173
healthy, 18 -45
n = 18
Health Status: healthy
Age Group: 18 -45
Sex: M
Population Size: 18
Sources: Page: p.173
Disc. AE: Vomiting, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Vomiting (grade 3, 5.6%)
Diarrhea (grade 3, 5.6%)
Sources: Page: p.173
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources: Page: p.250
healthy, 18-35
n = 16
Health Status: healthy
Age Group: 18-35
Sex: M+F
Population Size: 16
Sources: Page: p.250
Other AEs: Nausea, Diarrhea...
Other AEs:
Nausea (grade 1-2)
Diarrhea (grade 1-2)
Abdominal pain (grade 1-2)
Headache (grade 1-2)
Taste disturbance (grade 1-2)
Dizziness (grade 1-2)
Sources: Page: p.250
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.57
unhealthy, 18-83
n = 224
Health Status: unhealthy
Condition: Community-acquired pneumonia
Age Group: 18-83
Sex: M+F
Population Size: 224
Sources: Page: p.57
Disc. AE: Vomiting, Nausea...
Other AEs: Headache, Taste perversion...
AEs leading to
discontinuation/dose reduction:
Vomiting (grade 3, 1.4%)
Nausea (grade 3, 0.45%)
Alanine aminotransferase increase (grade 3, 0.45%)
Aspartate aminotransferase increase (grade 3, 0.45%)
Other AEs:
Headache (4.1%)
Taste perversion (3.6%)
Diarrhea (12.7%)
Sources: Page: p.57
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Other AEs: Acute hepatic failure, Liver injury...
Other AEs:
Acute hepatic failure (grade 4-5)
Liver injury (grade 4-5)
Hepatitis fulminant (grade 4)
Hepatic necrosis (grade 4)
Hepatic enzymes increased (grade 2)
Hepatitis (grade 2)
Jaundice (grade 2)
Electrocardiogram QTc interval prolonged
Visual disturbances
Blurred vision
Diplopia
Loss of consciousness
Vagal reaction
Sources: Page: p.12
AEs

AEs

AESignificanceDosePopulation
Alanine aminotransferase increase Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.436
unhealthy, 13-72
n = 232
Health Status: unhealthy
Condition: Group A beta-hemolytic streptococcal tonsillitis/pharyngitis
Age Group: 13-72
Sex: M+F
Population Size: 232
Sources: Page: p.436
Allergic reaction Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.436
unhealthy, 13-72
n = 232
Health Status: unhealthy
Condition: Group A beta-hemolytic streptococcal tonsillitis/pharyngitis
Age Group: 13-72
Sex: M+F
Population Size: 232
Sources: Page: p.436
Aspartate aminotransferase increase Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.436
unhealthy, 13-72
n = 232
Health Status: unhealthy
Condition: Group A beta-hemolytic streptococcal tonsillitis/pharyngitis
Age Group: 13-72
Sex: M+F
Population Size: 232
Sources: Page: p.436
Lactate dehydrogenase increased Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.436
unhealthy, 13-72
n = 232
Health Status: unhealthy
Condition: Group A beta-hemolytic streptococcal tonsillitis/pharyngitis
Age Group: 13-72
Sex: M+F
Population Size: 232
Sources: Page: p.436
Nausea 3.8%
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.1598
unhealthy, 17–64
n = 140
Health Status: unhealthy
Condition: asthma
Age Group: 17–64
Sex: M+F
Population Size: 140
Sources: Page: p.1598
Nausea 5.3%
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.1598
unhealthy, 17–64
n = 140
Health Status: unhealthy
Condition: asthma
Age Group: 17–64
Sex: M+F
Population Size: 140
Sources: Page: p.1598
Diarrhea 9.8%
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.1598
unhealthy, 17–64
n = 140
Health Status: unhealthy
Condition: asthma
Age Group: 17–64
Sex: M+F
Population Size: 140
Sources: Page: p.1598
Diarrhea grade 3, 5.6%
Disc. AE
1600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources: Page: p.173
healthy, 18 -45
n = 18
Health Status: healthy
Age Group: 18 -45
Sex: M
Population Size: 18
Sources: Page: p.173
Vomiting grade 3, 5.6%
Disc. AE
1600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 1 times / day
Sources: Page: p.173
healthy, 18 -45
n = 18
Health Status: healthy
Age Group: 18 -45
Sex: M
Population Size: 18
Sources: Page: p.173
Abdominal pain grade 1-2
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources: Page: p.250
healthy, 18-35
n = 16
Health Status: healthy
Age Group: 18-35
Sex: M+F
Population Size: 16
Sources: Page: p.250
Diarrhea grade 1-2
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources: Page: p.250
healthy, 18-35
n = 16
Health Status: healthy
Age Group: 18-35
Sex: M+F
Population Size: 16
Sources: Page: p.250
Dizziness grade 1-2
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources: Page: p.250
healthy, 18-35
n = 16
Health Status: healthy
Age Group: 18-35
Sex: M+F
Population Size: 16
Sources: Page: p.250
Headache grade 1-2
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources: Page: p.250
healthy, 18-35
n = 16
Health Status: healthy
Age Group: 18-35
Sex: M+F
Population Size: 16
Sources: Page: p.250
Nausea grade 1-2
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources: Page: p.250
healthy, 18-35
n = 16
Health Status: healthy
Age Group: 18-35
Sex: M+F
Population Size: 16
Sources: Page: p.250
Taste disturbance grade 1-2
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources: Page: p.250
healthy, 18-35
n = 16
Health Status: healthy
Age Group: 18-35
Sex: M+F
Population Size: 16
Sources: Page: p.250
Diarrhea 12.7%
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.57
unhealthy, 18-83
n = 224
Health Status: unhealthy
Condition: Community-acquired pneumonia
Age Group: 18-83
Sex: M+F
Population Size: 224
Sources: Page: p.57
Taste perversion 3.6%
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.57
unhealthy, 18-83
n = 224
Health Status: unhealthy
Condition: Community-acquired pneumonia
Age Group: 18-83
Sex: M+F
Population Size: 224
Sources: Page: p.57
Headache 4.1%
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.57
unhealthy, 18-83
n = 224
Health Status: unhealthy
Condition: Community-acquired pneumonia
Age Group: 18-83
Sex: M+F
Population Size: 224
Sources: Page: p.57
Alanine aminotransferase increase grade 3, 0.45%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.57
unhealthy, 18-83
n = 224
Health Status: unhealthy
Condition: Community-acquired pneumonia
Age Group: 18-83
Sex: M+F
Population Size: 224
Sources: Page: p.57
Aspartate aminotransferase increase grade 3, 0.45%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.57
unhealthy, 18-83
n = 224
Health Status: unhealthy
Condition: Community-acquired pneumonia
Age Group: 18-83
Sex: M+F
Population Size: 224
Sources: Page: p.57
Nausea grade 3, 0.45%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.57
unhealthy, 18-83
n = 224
Health Status: unhealthy
Condition: Community-acquired pneumonia
Age Group: 18-83
Sex: M+F
Population Size: 224
Sources: Page: p.57
Vomiting grade 3, 1.4%
Disc. AE
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.57
unhealthy, 18-83
n = 224
Health Status: unhealthy
Condition: Community-acquired pneumonia
Age Group: 18-83
Sex: M+F
Population Size: 224
Sources: Page: p.57
Blurred vision
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Diplopia
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Electrocardiogram QTc interval prolonged
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Loss of consciousness
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Vagal reaction
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Visual disturbances
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Hepatic enzymes increased grade 2
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Hepatitis grade 2
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Jaundice grade 2
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Hepatic necrosis grade 4
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Hepatitis fulminant grade 4
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Acute hepatic failure grade 4-5
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Liver injury grade 4-5
800 mg 1 times / day multiple, oral
Recommended
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.12
unhealthy
Health Status: unhealthy
Condition: Community-acquired pneumonia
Sources: Page: p.12
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
weak
weak (co-administration study)
Comment: Co-administration of telithromycin increased the bioavailability of metropolol resulted in in ~1.4 fold increase in both AUC and Cmax; there was no pharmacokinetic effect on paroxetine
Page: 33.0
yes [IC50 1.8 uM]
yes [IC50 11 uM]
yes [IC50 12 uM]
yes [Ki 3.65 uM]
yes (co-administration study)
Comment: Cisapride: Steady-state peak plasma concentrations of cisapride (an agent with the potential to increase QT interval) were increased by 95% when co-administered with repeated doses of telithromycin; Simvastatin: When simvastatin was co-administered with telithromycin, there was a 5.3-fold increase in simvastatin Cmax, an 8.9-fold increase in simvastatin AUC, a 15-fold increase in the simvastatin active metabolite Cmax, and a 12-fold increase in the simvastatin active metabolite AUC; Midazolam: Concomitant administration of telithromycin with intravenous or oral midazolam resulted in 2- and 6-fold increases, respectively, in the AUC of midazolam due to inhibition of CYP 3A4- dependent metabolism of midazolam;
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (co-administration study)
Comment: Itraconazole: A multiple-dose interaction study with itraconazole showed that Cmax of telithromycin was increased by 22% and AUC by 54%; Ketoconazole: A multiple-dose interaction study with ketoconazole showed that Cmax of telithromycin was increased by 51% and AUC by 95%;
Page: 3.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection.
1997 Oct
Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
1998 Nov
In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4.
2000 Oct
Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment.
2001 Aug
Telithromycin-induced acute interstitial nephritis: a first case report.
2004 Aug
In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis.
2005 Apr
Verapamil toxicity resulting from a probable interaction with telithromycin.
2005 Feb
Pill esophagitis caused by telithromycin: a case report.
2006 Jun
Acute hepatitis attack after exposure to telithromycin.
2007 Aug
Cellular imaging predictions of clinical drug-induced liver injury.
2008 Sep
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.
2009 Jun 15
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
2010 Dec
Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.
2010 Jan
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
2013 Nov
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
2015 Jun
Patents

Patents

Sample Use Guides

800 mg taken orally once every 24 hours
Route of Administration: Oral
The clinical isolates tested were an erythromycinsusceptible Staphylococcus aureus (011UC4), an erythromycin-resistant Streptococcus pneumoniae (030MV2) and a β-lactamase-producing H. influenzae (350RD7). The MICs of telithromycin for these organisms, as measured by a two-fold agar dilution method,4 were 0.04, 0.15 and 0.6 mg/L, respectively.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:53:08 UTC 2021
Edited
by admin
on Fri Jun 25 21:53:08 UTC 2021
Record UNII
KI8H7H19WL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TELITHROMYCIN
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
TELITHROMYCIN [MART.]
Common Name English
TELITHROMYCIN [MI]
Common Name English
TELITHROMYCIN [WHO-DD]
Common Name English
TELITHROMYCIN [USAN]
Common Name English
LEVVIAX
Brand Name English
KETEK
Brand Name English
TELITHROMYCIN [EMA EPAR]
Common Name English
TELITHROMYCIN [VANDF]
Common Name English
ERYTHROMYCIN,3-DE((2,6-DIDEOXY-3-C-METHYL-3-O-METHYL-.ALPHA.-L-RIBO-HEXOPYRANOSYL)OXY)-11,12-DIDEOXY-6-O-METHYL-3-OXO-12,11-(OXYCARBONYL((4-(4-(3-PYRIDINYL)-1H-IMIDAZOL-1-YL)BUTYL)IMINO)-
Common Name English
NSC-758940
Code English
HMR-3647
Code English
TELITHROMYCIN [INN]
Common Name English
TELITHROMYCIN [JAN]
Common Name English
TELITHROMYCIN [ORANGE BOOK]
Common Name English
HMR 3647
Code English
TELITHROMYCIN [HSDB]
Common Name English
Classification Tree Code System Code
WHO-ATC J01FA15
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
EMA ASSESSMENT REPORTS LEVVIAX (WITHDRAWN: TONSILLITIS)
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
EMA ASSESSMENT REPORTS LEVVIAX (WITHDRAWN: PHARYNGITIS)
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
NDF-RT N0000011414
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
WHO-VATC QJ01FA15
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
NDF-RT N0000011414
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
NCI_THESAURUS C261
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
EMA ASSESSMENT REPORTS KETEK (AUTHORIZED: TONSILLITIS)
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
EMA ASSESSMENT REPORTS KETEK (AUTHORIZED: PHARYNGITIS)
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
NDF-RT N0000175492
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
LIVERTOX 929
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
NDF-RT N0000011414
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
Code System Code Type Description
LACTMED
Telithromycin
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
PUBCHEM
3002190
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
MERCK INDEX
M10531
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY Merck Index
INN
7803
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
MESH
C106791
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
CAS
191114-48-4
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
WIKIPEDIA
TELITHROMYCIN
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
EPA CompTox
191114-48-4
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
CAS
173838-31-8
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
SUPERSEDED
EVMPD
SUB12606MIG
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
HSDB
7359
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
NCI_THESAURUS
C61963
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
RXCUI
274786
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY RxNorm
FDA UNII
KI8H7H19WL
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
ChEMBL
CHEMBL1136
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
DRUG CENTRAL
2581
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
DRUG BANK
DB00976
Created by admin on Fri Jun 25 21:53:08 UTC 2021 , Edited by admin on Fri Jun 25 21:53:08 UTC 2021
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
URINE
METABOLIC ENZYME -> INHIBITOR
Ki
EXCRETED UNCHANGED
FECAL
BINDER->LIGAND
Total in vitro protein binding is approximately 60% to 70% and is primarily due to human serum albumin. Protein binding is not modified in elderly subjects and in patients with hepatic impairment.
BINDING
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> INDUCER
POTENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC INTRAVENOUS INFUSION